Literature DB >> 14644329

Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.

Kristina Trenz1, Sebastian Lugowski, Ute Jahrsdörfer, Silke Jainta, Walther Vogel, Günter Speit.   

Abstract

We are studying the induction and repair of DNA damage in lymphocytes of women from families with familial breast cancer and mutations in the breast cancer susceptibility genes BRCA1 and BRCA2. Our previous results indicated a close relationship between the presence of a BRCA1 mutation and sensitivity for the induction of micronuclei by gamma irradiation and hydrogen peroxide (H2O2). To further characterize the mutagen sensitivity and to better understand the underlying mechanisms, we now tested the effect of various cytostatics on the micronucleus frequencies in lymphocytes of women with various BRCA1 mutations in comparison to controls. The results presented here indicate enhanced sensitivity towards bleomycin, cisplatin, cyclophosphamide and bischloroethylnitosurea (BCNU). However, mutagen sensitivity towards cisplatin and BCNU was not accompanied by enhanced induction of sister chromatid exchanges (SCE), suggesting that intrachromosomal recombination is not affected. In contrast to the various DNA-damaging agents, there was no clear difference in the response to vincristine and taxol. FISH analysis revealed that the two aneugens mainly induced centromere-positive micronuclei to a similar extent in lymphocytes with and without a BRCA1 mutation. We conclude that cells containing a heterozygous mutation in BRCA1 are more sensitive towards different kinds of DNA damage in accordance with the proposed central role of BRCA1 in maintaining genomic integrity. Although BRCA1 has been shown to interact with the mitotic spindle, spindle poisons do not cause enhanced induction of micronuclei. Since some of the DNA-damaging mutagens tested here are used as cytostatics in breast cancer chemotherapy, it might be that women with a BRCA1 mutation are at higher risk for the induction of mutations and secondary cancers by standard therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644329     DOI: 10.1016/j.mrrev.2003.06.011

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  9 in total

1.  Induction of homologous recombination following in utero exposure to DNA-damaging agents.

Authors:  Bijal Karia; Jo Ann Martinez; Alexander J R Bishop
Journal:  DNA Repair (Amst)       Date:  2013-09-10

2.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

Review 3.  Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.

Authors:  Fatemeh Sadeghi; Marzieh Asgari; Mojdeh Matloubi; Maral Ranjbar; Nahid Karkhaneh Yousefi; Tahereh Azari; Majid Zaki-Dizaji
Journal:  Biol Proced Online       Date:  2020-10-01       Impact factor: 3.244

Review 4.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

Review 5.  Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.

Authors:  F Cardinale; P Bruzzi; C Bolognesi
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

6.  DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers.

Authors:  J Kotsopoulos; Z Chen; K A Vallis; A Poll; P Ainsworth; S A Narod
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640

7.  Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility.

Authors:  Claudia Bolognesi; Paolo Bruzzi; Viviana Gismondi; Samantha Volpi; Valeria Viassolo; Simona Pedemonte; Liliana Varesco
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

8.  Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond.

Authors:  Lidiya Luzhna; Palak Kathiria; Olga Kovalchuk
Journal:  Front Genet       Date:  2013-07-11       Impact factor: 4.599

Review 9.  Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.

Authors:  Fengxia Chen; Feifei Pu
Journal:  Onco Targets Ther       Date:  2017-04-06       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.